Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type

Journal of Pathology

Volumn 238, Issue 3, 2016, Pages 389-400

  Karnezis, Anthony N ^a   Wang, Yemin ^a   Ramos, Pilar ^b   Hendricks, William P D ^b   Oliva, Esther ^c   D'Angelo, Emanuela ^d   Prat, Jaime ^d   Nucci, Marisa R ^e   Nielsen, Torsten O ^a   Chow, Christine ^f   Leung, Samuel ^f   Kommoss, Friedrich ^g   Kommoss, Stefan ^h   Silva, Annacarolina ^c   Ronnett, Brigitte M ⁱ   Rabban, Joseph T ^j   Bowtell, David D ^k   Weissman, Bernard E ^l   Trent, Jeffrey M ^b   Gilks, C Blake ^a   Huntsman, David G ^a,f,m   more..

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g SYNLAB ACADEMY   (Germany)

^h UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

ⁱ JOHNS HOPKINS HOSPITAL   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k PETER MACCALLUM CANCER CENTRE   (Australia)

^l UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^m BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

more..

Author keywords

epigenetic silencing; HDAC inhibitor; hypercalcaemic type; rhabdoid tumour; small cell carcinoma; SMARCA2 BRM; SMARCA4 BRG1; SMARCB1 INI1; SWI SNF; trichostatin A

Indexed keywords

BRG1 PROTEIN; BRM PROTEIN; TRICHOSTATIN A; ADENOSINE TRIPHOSPHATASE; DNA BINDING PROTEIN; DNA HELICASE; NONHISTONE PROTEIN; NUCLEAR PROTEIN; SMARCA2 PROTEIN, HUMAN; SMARCA4 PROTEIN, HUMAN; SMARCB1 PROTEIN, HUMAN; SWI/SNF RELATED MATRIX ASSOCIATED ACTIN DEPENDENT REGULATOR OF CHROMATIN SUBFAMILY B MEMBER 1; TRANSCRIPTION FACTOR; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; DUAL LOSS PHENOTYPE; ENDOMETRIUM TUMOR; EPIGENETIC REPRESSION; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; OVARIAN CANCER CELL LINE; OVARY TUMOR; PHENOTYPE; PRIORITY JOURNAL; SMALL CELL CARCINOMA OF THE OVARY HYPERCALCEMIC TYPE; TISSUE MICROARRAY; TUMOR CLASSIFICATION; CARCINOMA, SMALL CELL; CELL PROLIFERATION; CELL TRANSFORMATION; DEFICIENCY; GENE SILENCING; GENETICS; HYPERCALCEMIA; METABOLISM; MUTATION; OVARIAN NEOPLASMS; PHYSIOLOGY; TUMOR CELL LINE;

ADENOSINE TRIPHOSPHATASES; BIOMARKERS, TUMOR; CARCINOMA, SMALL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA HELICASES; DNA-BINDING PROTEINS; FEMALE; GENE SILENCING; HUMANS; HYPERCALCEMIA; IMMUNOHISTOCHEMISTRY; MUTATION; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; SMARCB1 PROTEIN; TRANSCRIPTION FACTORS;

EID: 84956774384     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4633     Document Type: Article

References (44)

1. Young RH, Oliva E, Scully RE,. Small cell carcinoma of the ovary, hypercalcemic type: a clinicopathological analysis of 150 cases. Am J Surg Pathol 1994; 18: 1102-1116.
2. Ramos P, Karnezis AN, Craig DW, et al., Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nature Genet 2014; 46: 427-429.
3. Witkowski L, Carrot-Zhang J, Albrecht S, et al., Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nature Genet 2014; 46: 438-443.
4. Kupryjanczyk J, Dansonka-Mieszkowska A, Moes-Sosnowska J, et al., Ovarian small cell carcinoma of hypercalcemic type-evidence of germline origin and smarca4 gene inactivation. A pilot study. Pol J Pathol 2013; 64: 238-246.
5. Jelinic P, Mueller JJ, Olvera N, et al., Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. Nature Genet 2014; 46: 424-426.
6. Hargreaves DC, Crabtree GR,. ATP-dependent chromatin remodeling: genetics, genomics and mechanisms. Cell Res 2011; 21: 396-420.
7. Neigeborn L, Carlson M,. Genes affecting the regulation of SUC2 gene expression by glucose repression in Saccharomyces cerevisiae. Genetics 1984; 108: 845-858.
8. Stern M, Jensen R, Herskowitz I,. Five SWI genes are required for expression of the HO gene in yeast. J Mol Biol 1984; 178: 853-868.
9. Kadoch C, Hargreaves DC, Hodges C, et al., Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nature Genet 2013; 45: 592-601.
10. Shain AH, Pollack JR,. The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PloS One 2013; 8: e55119.
11. Oike T, Ogiwara H, Tominaga Y, et al., A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. Cancer Res 2013; 73: 5508-5518.
12. Hoffman GR, Rahal R, Buxton F, et al., Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. Proc Natl Acad Sci U S A 2014; 111: 3128-3133.
13. Helming KC, Wang X, Roberts CW,. Vulnerabilities of mutant SWI/SNF complexes in cancer. Cancer Cell 2014; 26: 309-317.
14. Alkushi A, Clarke BA, Akbari M, et al., Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. Mod Pathol 2007; 20: 1156-1165.
15. Ramos P, Karnezis AN, Hendricks WPD, et al., Loss of the tumor suppressor SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). Rare Diseases 2014; 2: e967148.
16. Silva EG, Deavers MT, Bodurka DC, et al., Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma? Int J Gynecol Pathol 2006; 25: 52-58.
17. Reisman DN, Strobeck MW, Betz BL, et al., Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression. Oncogene 2002; 21: 1196-1207.
18. Strobeck MW, DeCristofaro MF, Banine F, et al., The BRG-1 subunit of the SWI/SNF complex regulates CD44 expression. J Biol Chem 2001; 276: 9273-9278.
19. Strobeck MW, Reisman DN, Gunawardena RW, et al., Compensation of BRG-1 function by Brm: insight into the role of the core SWI-SNF subunits in retinoblastoma tumor suppressor signaling. J Biol Chem 2002; 277: 4782-4789.
20. Yamamichi N, Inada K, Ichinose M, et al., Frequent loss of Brm expression in gastric cancer correlates with histologic features and differentiation state. Cancer Res 2007; 67: 10727-10735.
21. Banine F, Bartlett C, Gunawardena R, et al., SWI/SNF chromatin-remodeling factors induce changes in DNA methylation to promote transcriptional activation. Cancer Res 2005; 65: 3542-3547.
22. Anglesio MS, Wiegand KC, Melnyk N, et al., Correction: type-specific cell line models for type-specific ovarian cancer research. PLoS One 2013; 8.
23. Dunaief JL, Strober BE, Guha S, et al., The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest. Cell 1994; 79: 119-130.
24. Muchardt C, Bourachot B, Reyes JC, et al., ras transformation is associated with decreased expression of the brm/SNF2α ATPase from the mammalian SWI-SNF complex. EMBO J 1998; 17: 223-231.
25. Strober BE, Dunaief JL, Guha, et al. Functional interactions between the hBRM/hBRG1 transcriptional activators and the pRB family of proteins. Mol Cell Biol 1996; 16: 1576-1583.
26. Strobeck MW, Knudsen KE, Fribourg AF, et al., BRG-1 is required for RB-mediated cell cycle arrest. Proc Natl Acad Sci U S A 2000; 97: 7748-7753.
27. Witkowski L, Lalonde E, Zhang J, et al., Familial rhabdoid tumour 'avant la lettre'-from pathology review to exome sequencing and back again. J Pathol 2013; 231: 35-43.
28. Kuo KT, Liang CW, Hsiao CH, et al., Downregulation of BRG-1 repressed expression of CD44s in cervical neuroendocrine carcinoma and adenocarcinoma. Mod Pathol 2006; 19: 1570-1577.
29. Carlson JW, Nucci MR, Brodsky J, et al., Biomarker-assisted diagnosis of ovarian, cervical and pulmonary small cell carcinomas: the role of TTF-1, WT-1 and HPV analysis. Histopathology 2007; 51: 305-312.
30. Stoler MH, Mills SE, Gersell DJ, et al., Small-cell neuroendocrine carcinoma of the cervix. A human papillomavirus type 18-associated cancer. Am J Surg Pathol 1991; 15: 28-32.
31. Gao J, Aksoy BA, Dogrusoz U, et al., Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6: pl1.
32. Cerami E, Gao J, Dogrusoz U, et al., The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401-404.
33. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.
34. Bashashati A, Ha G, Tone A, et al., Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol 2013; 231: 21-34.
35. Wilson BG, Helming KC, Wang X, et al., Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation. Mol Cell Biol 2014; 34: 1136-1144.
36. Reisman DN, Sciarrotta J, Wang W, et al., Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. Cancer Res 2003; 63: 560-566.
37. Matsubara D, Kishaba Y, Ishikawa S, et al., Lung cancer with loss of BRG1/BRM, shows epithelial mesenchymal transition phenotype and distinct histologic and genetic features. Cancer Sci 2013; 104: 266-273.
38. Huang HN, Lin MC, Huang WC, et al., Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma. Mod Pathol 2014; 27: 983-990.
39. Agaimy A., The expanding family of SMARCB1(INI1)-deficient neoplasia: implications of phenotypic, biological, and molecular heterogeneity. Adv Anat Pathol 2014; 21: 394-410.
40. Lee CH, Marino-Enriquez A, Ou W, et al., The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor. Am J Surg Pathol 2012; 36: 641-653.
41. Kahali B, Yu J, Marquez SB, et al., The silencing of the SWI/SNF subunit and anticancer gene BRM in Rhabdoid tumors. Oncotarget 2014; 5: 3316-3332.
42. Li L, Fan XS, Xia QY, et al., Concurrent loss of INI1, PBRM1, and BRM expression in epithelioid sarcoma: implications for the cocontributions of multiple SWI/SNF complex members to pathogenesis. Hum Pathol 2014; 45: 2247-2254.
43. Yamamichi N, Yamamichi-Nishina M, Mizutani T, et al., The Brm gene suppressed at the post-transcriptional level in various human cell lines is inducible by transient HDAC inhibitor treatment, which exhibits antioncogenic potential. Oncogene 2005; 24: 5471-5481.
44. Foulkes WD, Clarke BA, Hasselblatt M, et al., No small surprise-small cell carcinoma of the ovary, hypercalcaemic type, is a malignant rhabdoid tumour. J Pathol 2014; 233: 209-214.